News

8. Dezember 2016

Probiodrug AG

Innovative Phase II study design of Glutaminylcyclase Inhibitor PQ912 
in early Alzheimer's disease

Poster presentation at CTAD, San Diego, 8-10 December 2016

5. Dezember 2016

NOXXON PHARMA

NOXXON PHARMA ANNOUNCES NEW PRECLINICAL DATA SHOWING SYNERGY OF LEAD COMPOUND NOX-A12 WITH NATURAL KILLER (NK) CELL MEDIATED THERAPIES

THESE DATA WILL BE PRESENTED AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) CONFERENCE

24. November 2016

Emperra GmbH E-Health Technologies

Emperra GmbH E-Health Technologies was announced Business Worldwide Magazine's (BWM) 2016 Company of the Year Award/Medical Device Industry Europe for its innovative diabetes management system.

16. November 2016

Probiodrug AG

Amyloid-beta (Abeta) aggregate-clearing by the murine anti-pyroglutamate-3 Abeta IgG2a monoclonal antibody PBD-C06 with and without a complement mutation in an Alzheimer's mouse model

14. November 2016

Probiodrug AG

Probiodrug to attend US Life Sciences Conferences in November 2016

10. November 2016

Probiodrug AG

Probiodrug reports Third Quarter 2016 Business Update

3. November 2016

Probiodrug AG

Probiodrug AG to Publish its Third Quarter 2016 Business Update on 10 November 2016

27. Oktober 2016

Probiodrug AG

Probiodrug to present at European Life Sciences Conferences

Attendance at key conferences in November 2016

11. Oktober 2016

Emperra GmbH E-Health Technologies

Innovativer Versorgungsvertrag zwischen AOK Nordost und Emperra geschlossen

Neuer digitaler Betreuungsansatz für insulinpflichtige Diabetiker

Die technische Basis bildet das von Emperra entwickelte ESYSTA®-System. Es ermöglicht die unmittelbare Übertragung sowohl der gemessenen...

11. Oktober 2016

Probiodrug AG

Probiodrug to present at US and Japanese Life Science Conferences in October 2016

Seiten